Deals Analysis

Features

These were the biggest pharmaceutical deals in early 2022

GlobalData tracks the latest acquisitions, mergers, venture financing and asset transactions in the pharmaceutical sector.

Data Journalism Team

Features

Top and emerging locations for M&A deals in the pharmaceutical industry

Features

Inside Philip Morris’ controversial Vectura acquisition

Deals

Science park merger creates UK’s largest life sciences ecosystem

Deals

AZ’s proposed acquisition of rare disease-focused Alexion gets US clearance

Features

Exscientia raises $100m Series C funding to develop fully autonomous drug design

Features

SIRION and Sanofi partner on next-gen AAV gene therapy vectors

Features

Merck-Pandion acquisition: re-balancing immune response to treat autoimmune disease

Features

Veteran investor Dr Robert Glassman talks life sciences, immunotherapy and Umoja

Deals

Targeting immune diseases: Longwood Fund founds ImmuneID with $17m financing

Deals

Precision medicine in AMD: SPAC merger sees Gemini make its public debut

Features

Imcyse closes €21.3m Series B as new partner Pfizer takes equity stake

Features

AbbVie and Caribou team up on next-gen off-the-shelf CAR-T therapies

Features

Q&A with SVB’s Nooman Haque: what does 2021 have in store for healthcare investment?

Features

Q&A with Goodwin’s Andrew Harrow: exploring the pharma deals outlook in 2021

Deals

Horizon acquires Viela for $3bn to drive innovation and long-term growth

Features

TCR-T cell therapies for cancer: TScan raises $100m in Series C round

Features

Bispecific antibodies and cancer: Lilly and Merus team up on T cell engager therapies

Features

Exploring dark antigens: Enara and Boehringer Ingelheim sign oncology partnership

Deals

Phesi and Sensyne to collaborate on synthetic control arms for clinical trials

Features

Disease-cancelling drugs: Immuneering raises $62m in Series B round

Features

Biopharma M&A: EY analysts optimistic for 2021 deals after a mixed 2020

Dashboards

Pharma November deals snapshot

Features

Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

Features

Targeting ‘undruggable’ proteins: Frontier collaborates with AbbVie

Features

Applying AI to global health challenges: Gates Foundation awards $4.2m to Exscientia

Features

Spotlight on rare neurological diseases: Noema closes $60.8m Series A round

Features

Investing in innovative biotechs with Novo Ventures

Deals

SynOx raises €37m in Series A to develop emactuzumab for rare cancer TGCT

Features

BioMarin and Deep Genomics team up on AI rare disease drug discovery

Features

Merck acquires VelosBio: exploring the promise of ROR1 in cancer

Features

Spotlight on Zolgensma: REGENXBIO receives $80m from Novartis for AAV vector

Features

Calliditas takes control of Genkyotex: expanding the rare disease pipeline

Features

AstraZeneca and Fusion team up on oncology radiopharmaceuticals

Features

Araris raises CHF15.2m to support its next-gen ADCs

Deals

Next-generation cell therapies: Be Bio raises $52m to develop B cell medicines

Features

Twist and Neogene partner to develop next-gen T cell therapies

Deals

Exscientia, Blue Oak partner to explore potential of bispecific drugs in CNS